⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethoxycarbonyl Group SCHEMBL28048125 | 0.81 | MTNR1A (0.35) | — | |
| SCHEMBL5123913 | 0.80 | HTT (0.38) | — | |
| SCHEMBL19510786 | 0.80 | ALDH1A1 (0.48) | — | |
| SCHEMBL2221308 | 0.77 | KDM4E (0.40) | — | |
| SCHEMBL2017242 | 0.77 | TSHR (0.39) | — | |
| SCHEMBL30756042 | 0.76 | — | — | |
| SCHEMBL12015 | 0.76 | CCR1 (0.41) | — | |
| SCHEMBL29520064 | 0.76 | CCR1 (0.41) | — | |
| SCHEMBL2632782 | 0.76 | — | — | |
| SCHEMBL3930494 | 0.76 | FGFR1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1045 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2702044-B1 | PROCESS FOR RILPIVIRINE | HETERO RESEARCH FOUNDATION (IN) | 2017-03-22 | — | — | EP | claimed |
| CN-103443074-B | Heterocyclic amine derivative | HOFFMAN-LA ROCHE LTD. (CH) | 2016-04-13 | — | — | CN | claimed |
| CN-104320972-A | Herbicidal composition comprising uracil compound as active ingredient | DONGBU FARM HANNONG CO LTD | 2015-01-28 | — | — | CN | claimed |
| US-20140228385-A1 | PROCESS FOR RILPIVIRINE | HETERO RESEARCH FOUNDATION (IN) | 2014-08-14 | — | — | US | claimed |
| EP-2702044-A2 | PROCESS FOR RILPIVIRINE | Hetero Research Foundation (IN) | 2014-03-05 | — | — | EP | claimed |
| WO-2012147091-A2 | PROCESS FOR RILPIVIRINE | HETERO RESEARCH FOUNDATION (IN) | 2012-11-01 | — | — | WO | claimed |
| JP-61063665-A | — | — | None | — | — | JP | disclosed |
| US-12629371-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| WO-2026101724-A1 | AMINO PYRIMIDINE AND AMINO TRIAZINE ANALOGS FOR TREATING CANCER | NEREID THERAPEUTICS INCORPORATED (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026041663-A1 | P2X7 RECEPTOR ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2026-02-26 | — | — | WO | disclosed |
| US-12545662-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12545682-B2 | Heterocyclic derivatives as P2X7 receptor antagonists | BREYE THERAPEUTICS APS (DK) | 2026-02-10 | — | — | US | disclosed |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| WO-1994012494-A1 | USE OF DIMETHYLBENZOFURANS AND DIMETHYLBENZOPYRANS AS 5-HT3 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-06-09 | — | — | WO | disclosed |
| US-5266570-A | Neuropsychiatric disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-11-30 | — | — | US | disclosed |
| EP-0532178-A1 | Methanoanthracenes as dopamine antagonists | ZENECA LIMITED (GB) | 1993-03-17 | — | — | EP | disclosed |
| EP-0246984-A2 | Sulfonyl urea herbicides, their preparation, compositions containing them and their use | RHONE-POULENC AGROCHIMIE (FR) | 1987-11-25 | — | — | EP | disclosed |
| JP-S6163665-A | 2-((3-PHENOXY)PROPYLAMINO)-4(1H)-PYRIMIDINONE DERIVATIVE | HOKURIKU SEIYAKU CO LTD | 1986-04-01 | — | — | JP | disclosed |
| US-4256738-A | BACTERICIDES, PYRIMIDINYL, QUINAZOLINYL | BOEHRINGER INGELHEIM GMBH (DE) | 1981-03-17 | — | — | US | disclosed |
| EP-0001981-A1 | 9-(Omega-heteroarylamino-alkylamino)-erythromycins, their salts, processes for their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1979-05-30 | — | — | EP | disclosed |